contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


magle-chemoswed-holding-reports-financial-results-for-third-quarter-2024

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed, a contract development and manufacturing organization (CDMO). Magle PharmaCept, an established sales and marketing company for the development and direct sales of the Groups medical technology products, and Magle Biopolymers A/S, a specialized manufacturing organization of Dextran technology.

Magle Chemoswed Holding

Magle Group (publ) reports strong Q3 2024 performance, with sales growth and strategic mergers positioning the company for future market expansion.Q3 2024 KEY INDICATORS Net sales amounted to...

<div class="mfn-preamble">Magle Group (publ) reports strong Q3 2024 performance, with sales growth and strategic mergers positioning the company for future market expansion.</div><div class="mfn-body">Q3 2024 KEY INDICATORS Net sales amounted to 64.6 MSEK (36.3). EBITDA equalled 26.5 MSEK (4.8). Operating profit (EBIT) is 13.7 MSEK (1.5) Profit after tax amounted to 9.6 MSEK (0.5)JAN-SEP 2024 KEY INDICATORS Net sales amounted to 148.8 MSEK (113.1). EBITDA equalled 38.8 MSEK (21.8). Operating profit (EBIT) is 19.2 MSEK (12.1) Profit after tax amounted to 12.7 MSEK (8.1)“As we close the third quarter of 2024, I am pleased to report strong progress for Magle Group. We have successfully completed the merger with PK Chemical A/S and are nearing completion with Amniotics AB. These strategic acquisitions bring valuable technologies that strengthen our mission to deliver innovative healthcare solutions. This quarter's results were positively impacted by the purchase price allocation (PPA) under IFRS, contributing a one-off, extraordinary income. Excluding the PPA adjustment, our underlying performance remains solid, with revenue for the quarter reaching 69.9 MSEK, up from 40.59 MSEK last year. Looking ahead, we remain focused on integrating our new businesses, driving growth, and achieving cost synergies. I am confident that our efforts will position us for sustained success.” said Justin Pierce, CEO.</div><div class="mfn-footer mfn-6592d21ec2a5">Contacts<hr>Justin Pierce, CEO, phone +46 (0)70 593 58 21, <a rel="noopener" href="mailto:justin.pierce@maglechemoswed.com">justin.pierce@maglechemoswed.com</a> </div><div class="mfn-footer mfn-about mfn-70935ab259f1">About Us<hr>The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on&nbsp;<a rel="noopener" href="http://www.maglechemoswed.com/">www.maglechemoswed.com</a> and <a rel="noopener" href="https://maglegroup.com/">www.maglegroup.com</a> and <a rel="noopener" href="http://www.maglepharmacept.com">www.maglepharmacept.com</a> and <a rel="noopener" href="https://maglebiopolymers.com/">www.maglebiopolymers.com</a>Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at <a rel="noopener" href="mailto:ca@vatorsec.se">ca@vatorsec.se</a> or +46 (0)8-580 065 99.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/550b5cc9-6003-4971-b28e-8cb4231c03f6/interim-report-q3-2024.pdf" class="mfn-primary">Interim Report Q3 2024</a></div>